Leftover radioactive materials from the US nuclear program, especially Uranium-233, are being utilized in developing targeted alpha therapy for cancer. Oak Ridge National Laboratory scientists have found Thorium-229, a byproduct of Uranium-233, useful in creating Actinium-225, which can precisely destroy cancer cells without affecting healthy tissue. This innovative treatment shows promise for various cancers, including lymphoma and prostate cancer, but its limited supply poses challenges. Targeted alpha therapy utilizes antibodies to direct radioactive particles specifically at tumors, minimizing side effects compared to traditional cancer therapies.
Targeted alpha therapy is a precise cancer-fighting tool that works like a tiny, guided missile aimed at cancer cells in the patient's body.
As Thorium-229 breaks down, it produces Actinium-225 (Ac-225), an isotope that can destroy tumors without harming surrounding healthy tissue.
Researchers believe targeted alpha therapy could treat a range of cancers, including lymphoma, prostate cancer, and breast cancer.
The biggest problem at the moment is that there is only a tiny supply of Thorium-229 in the entire world - only 45 grams.
Collection
[
|
...
]